The Impact of Chronic Bronchial Infection in COPD: A Proposal for Management

References

• Soriano JB, Kendrick PJ, Paulson KR; GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Soriano JB, Alfageme I, Miravitlles M, et al. Prevalence and determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol. 2021;57(1):61–69. doi:10.1016/j.arbr.2020.07.017
   PubMed Web of Science ®Google Scholar
• Agustí A, Hogg JC, Drazen JM. Update on the pathogenesis of Chronic obstructive pulmonary disease. N Engl J Med. 2019;381:1248–1256. doi:10.1056/NEJMra1900475
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: an European Respiratory Society/American Thoracic Society (ERS/ATS) guideline. Eur Respir J. 2017;49:1600791. doi:10.1183/13993003.00791-2016
   PubMed Web of Science ®Google Scholar
• Anzueto A, Miravitlles M. Chronic obstructive pulmonary disease exacerbations: a need for action. Am J Med. 2018;131:15–22. doi:10.1016/j.amjmed.2018.05.003
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Piñera P, Trigueros JA, et al. Spanish COPD guidelines (GesEPOC) 2021 update diagnosis and treatment of COPD exacerbation syndrome. Arch Bronconeumol. 2022;58:159–170. doi:10.1016/j.arbres.2021.05.011
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908. doi:10.2147/COPD.S139470
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931. doi:10.1136/thx.2005.040527
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Miralles C. Exacerbation Syndrome in COPD: a paradigm shift. Arch Bronconeumol. 2021;57(4):246–248. doi:10.1016/j.arbr.2020.07.021
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed December 16, 2021.
   Google Scholar
• Montes de Oca M, López Varela MV, Acuña A, et al. Incorporating new evidence on inhaled medications in COPD. The Latin American Chest Association (ALAT) 2019. Arch Bronconeumol. 2020;56(2):106–113. doi:10.1016/j.arbr.2019.09.002
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Calle M, Molina J, et al. Spanish COPD Guidelines (GesEPOC) 2021: updated Pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58:69–81. doi:10.1016/j.arbres.2021.03.005
   PubMed Web of Science ®Google Scholar
• López-Campos JL, Carrasco-Hernández L, Román Rodríguez L, Quintana-Gallego E, Carmona Bernal C, Alcázar Navarrete B. The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient. Arch Bronconeumol. 2020;56(4):242–248. doi:10.1016/j.arbres.2019.11.011
   PubMed Web of Science ®Google Scholar
• Ruano-Raviña A, Fernández-Villar A, López-Campos JL. Coping with low mortality and exacerbation rate differences between COPD triple therapy studies, and a proposal for upcoming studies. Arch Bronconeumol. 2020;56(5):336–338. doi:10.1016/j.arbr.2019.11.009
   PubMed Web of Science ®Google Scholar
• Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir Res. 2017;18(1):88. doi:10.1186/s12931-017-0570-5
   PubMed Web of Science ®Google Scholar
• Shafiek H, Verdú J, Iglesias A, et al. Inhaled corticosteroid dose is associated with Pseudomonas aeruginosa infection in severe COPD. BMJ Open Respir Res. 2021;8(1):e001067. doi:10.1136/bmjresp-2021-001067
   PubMed Web of Science ®Google Scholar
• Eklöf J, Ingebrigtsen TS, Sørensen R, et al. Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease. Thorax. 2021:thoraxjnl-2021-217160. doi: 10.1136/thoraxjnl-2021-217160
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled steroids, circulating eosinophils, chronic airway infection and pneumonia risk in chronic obstructive pulmonary disease: a network analysis. Am J Respir Crit Care Med. 2020;201(9):1078–1085. doi:10.1164/rccm.201908-1550OC
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Auladell-Rispau A, Monteagudo M, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021;30(160):210075. doi:10.1183/16000617.0075-2021
   PubMed Web of Science ®Google Scholar
• Wedzicha J, Calverley P, Albert R, et al. Prevention of COPD exacerbations: an European Respiratory Society/American Thoracic Society (ERS/ATS) guideline. Eur Respir J. 2017;50:1602265. doi:10.1183/13993003.02265-2016
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355–2365. doi:10.1056/NEJMra0800353
   PubMed Web of Science ®Google Scholar
• Tanno A, Fujino N, Yamada M, et al. Decreased expression of a phagocytic receptor Siglec-1 on alveolar macrophages in chronic obstructive pulmonary disease. Respir Res. 2020;21(1):30. doi:10.1186/s12931-020-1297-2
   PubMed Web of Science ®Google Scholar
• Millares L, Pascual S, Montón C, et al. Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients. BMC Pulm Med. 2019;19(1):112. doi:10.1186/s12890-019-0867-x
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Anzueto A. Chronic respiratory infection in patients with chronic obstructive pulmonary disease: what is the role of antibiotics? Int J Mol Sci. 2017;18:E1344. doi:10.3390/ijms18071344
   PubMed Web of Science ®Google Scholar
• Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(9):991–998. doi:10.1164/rccm.200509-1525OC
   PubMed Web of Science ®Google Scholar
• Zhang M, Li Q, Zhang XY, Ding X, Zhu D, Zhou X. Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease. Eur J Clin Microbiol Infect Dis. 2010;29:1487–1493. doi:10.1007/s10096-010-1027-7
   PubMed Web of Science ®Google Scholar
• Tufvesson E, Bjermer L, Ekberg M. Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammation. Int J Chron Obstruct Pulmon Dis. 2015;10:881–889. doi:10.2147/COPD.S78748
   PubMed Web of Science ®Google Scholar
• Finney LJ, Ritchie A, Pollard E, Johnston SL, Mallia P. Lower airway colonization and inflammatory response in COPD: a focus on Haemophilus influenzae. Int J Chron Obstruct Pulmon Dis. 2014;9:1119–1132. doi:10.2147/COPD.S54477
   PubMed Web of Science ®Google Scholar
• Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57:759–764. doi:10.1136/thorax.57.9.759
   PubMed Web of Science ®Google Scholar
• Leung JM, Tiew PY, Aogain M, et al. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respirology. 2017;22:634–650. doi:10.1111/resp.13032
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1090–1095. doi:10.1164/rccm.200210-1179OC
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, de la Rosa-carrillo D, Soler-Cataluna JJ, et al. Bronchial infection and temporal evolution of bronchiectasis in patients with chronic obstructive pulmonary disease. Clin Infect Dis. 2021;72(3):403–410. doi:10.1093/cid/ciaa069
   PubMed Web of Science ®Google Scholar
• Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J. 2004;23:685–691. doi:10.1183/09031936.04.00056804
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MÁ, Faner R, Oscullo G, et al. Chronic bronchial infection and incident cardiovascular events in chronic obstructive pulmonary disease patients: a long-term observational study. Respirology. 2021;26(8):776–785. doi:10.1111/resp.14086
   PubMed Web of Science ®Google Scholar
• Eklof J, Sorensen R, Ingebrigtsen TS, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2020;26:227–234. doi:10.1016/j.cmi.2019.06.011
   PubMed Web of Science ®Google Scholar
• Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med. 2013;107:10–22. doi:10.1016/j.rmed.2012.10.024
   PubMed Web of Science ®Google Scholar
• López-Campos JL, Miravitlles M, De la Rosa Carrillo D, Cantón R, Soler-Cataluña JJ, Martinez-Garcia MA. Current challenges in chronic bronchial infection in patients with chronic obstructive pulmonary disease. J Clin Med. 2020;9:E1639. doi:10.3390/jcm9061639
   PubMed Web of Science ®Google Scholar
• De la Rosa Carrillo D, López-Campos JL, Alcázar Navarrete B, et al. Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease. Arch Bronconeumol. 2020;56(10):651–664. doi:10.1016/j.arbres.2020.04.023
   PubMed Web of Science ®Google Scholar
• Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465–471. doi:10.1056/NEJMoa012561
   PubMed Web of Science ®Google Scholar
• Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J Suppl. 2002;36:9s–19s. doi:10.1183/09031936.02.00400302
   PubMedGoogle Scholar
• Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate COPD. Am J Respir Crit Care Med. 2012;186:716–723. doi:10.1164/rccm.201206-0996OC
   PubMed Web of Science ®Google Scholar
• Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Maiz L, Olveira C, et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. Arch Bronconeumol. 2018;54(2):79–87. doi:10.1016/j.arbr.2017.07.013
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M; Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–46. doi:10.1378/chest.116.1.40
   PubMed Web of Science ®Google Scholar
• Martínez-García MÁ, Faner R, Oscullo G, et al. Risk factors and relation with mortality of a new acquisition and persistence of Pseudomonas aeruginosa in COPD patients. COPD. 2021;18(3):333–340. doi:10.1080/15412555.2021.1884214
   PubMedGoogle Scholar
• Martinez-García MA, Rigau D, Barrecheguren M, et al. Long-term risk of mortality associated with isolation of Pseudomonas aeruginosa in COPD: a prognostic systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2022;17:371–382. doi:10.2147/COPD.S346294
   PubMed Web of Science ®Google Scholar
• Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(8):853–860. doi:10.1164/rccm.200709-1413OC
   PubMed Web of Science ®Google Scholar
• Boutou AK, Raste Y, Reid J, Alshafi K, Polkey MI, Hopkinson NS. Does a single Pseudomonas aeruginosa isolation predict COPD mortality? Eur Respir J. 2014;44(3):794–797. doi:10.1183/09031936.00023414
   PubMed Web of Science ®Google Scholar
• Araújo D, Shteinberg M, Aliberti S, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018;51:1701953. doi:10.1183/13993003.01953-2017
   PubMed Web of Science ®Google Scholar
• Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive pulmonary disease. Respir Res. 2019;20(1):113. doi:10.1186/s12931-019-1085-z
   PubMed Web of Science ®Google Scholar
• Polverino E, Dimakou K, Hurst J, et al. The overlap between bronchiectasis and chronic airways diseases: state of the art and future directions. Eur Respir J. 2018;52:pii: 1800328. doi:10.1183/13993003.00328-2018
   Web of Science ®Google Scholar
• Martínez-García MA, Miravitlles M. Bronchiectasis in COPD patients. More than a comorbidity? Int J Chron Obstruct Pulmon Dis. 2017;12:1401–1411. doi:10.2147/COPD.S132961
   PubMed Web of Science ®Google Scholar
• Chen CL, Huang Y, Yuan JJ, et al. The roles of bacteria and viruses in bronchiectasis exacerbation: a Prospective Study. Arch Bronconeumol. 2020;56(10):621–629. doi:10.1016/j.arbr.2019.12.014
   Web of Science ®Google Scholar
• Clancy RL, Crip Ps AW. An oral whole-cell killed nontypeable Haemophilus influenzae immunotherapeutic for the prevention of acute exacerbations of chronic airway disease. Int J Chron Obstruct Pulmon Dis. 2019;25(14):2423–2431. doi:10.2147/COPD.S217317
   Web of Science ®Google Scholar
• Cowan J, Mulpuru S, Abdallah SJ, et al. A randomized double-blind placebo-control feasibility trial of immunoglobulin treatment for prevention of recurrent acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2021;3(16):3275–3284. doi:10.2147/COPD.S338849
   Web of Science ®Google Scholar
• Anzueto A, Miravitlles M. Considerations for the correct diagnosis of chronic obstructive pulmonary disease and its management with bronchodilators. Chest. 2018;154:242–248. doi:10.1016/j.chest.2018.02.023
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Anzueto A. Antibiotic prophylaxis in COPD: why, when, and for whom? Pulm Pharmacol Ther. 2015;32:119–123. doi:10.1016/j.pupt.2014.05.002
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonization in COPD. Eur Respir J. 2009;34:1066–1071. doi:10.1183/09031936.00195608
   PubMed Web of Science ®Google Scholar
• Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10. doi:10.1186/1465-9921-11-10
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Marin A, Monsó E, et al. Colour of sputum is a marker of bacterial colonization in COPD. Respir Res. 2010;11:58. doi:10.1186/1465-9921-11-58
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa1104623
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (Columbus): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361–368. doi:10.1016/S2213-2600(14)70019-0
   PubMed Web of Science ®Google Scholar
• De la Rosa Carrillo D, Martínez-García MÁ, Barreiro E, et al. Effectiveness and safety of inhaled antibiotics in patients with chronic obstructive pulmonary disease. A Multicentre Observational Study. Arch Bronconeumol. 2022;58:11–21. doi:10.1016/j.arbres.2021.03.009
   PubMed Web of Science ®Google Scholar
• Chen K, Pleasants KA, Pleasants RA, et al. A systematic review and meta-analysis of sputum purulence to predict bacterial infection in COPD exacerbations. COPD. 2020;17(3):311–317. doi:10.1080/15412555.2020.1766433
   PubMedGoogle Scholar
• Sethi S, Anzueto A, Miravitlles M, et al. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease. Infection. 2016;44:65–76. doi:10.1007/s15010-015-0833-3
   PubMed Web of Science ®Google Scholar
• White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax. 2003;58(8):680–685. doi:10.1136/thorax.58.8.680
   PubMed Web of Science ®Google Scholar
• Armitage MN, Spittle DA, Turner AM. A systematic review and meta-analysis of the prevalence and impact of pulmonary bacterial colonisation in stable state Chronic Obstructive Pulmonary Disease (COPD). Biomedicines. 2021;10(1):81. doi:10.3390/biomedicines10010081
   PubMed Web of Science ®Google Scholar
• Cardoso J, Ferreira AJ, Guimarães M, Oliveira AS, Simão P, Sucena M. Treatable Traits in COPD - A Proposed Approach. Int J Chron Obstruct Pulmon Dis. 2021;18(16):3167–3182. doi:10.2147/COPD.S330817
   Web of Science ®Google Scholar
• Pérez de Llano L, Miravitlles M, Golpe R, et al. A proposed approach to Chronic Airway Disease (CAD) using therapeutic goals and treatable traits: a look to the future. Int J Chron Obstruct Pulmon Dis. 2020;15:2091–2100. doi:10.2147/COPD.S263430
   PubMed Web of Science ®Google Scholar
• Monso E. Look at the wood and not at the tree: the microbiome in chronic obstructive lung disease and cystic fibrosis. Arch Bronconeumol. 2020;56:5–6.
   PubMed Web of Science ®Google Scholar
• Traversi L, Miravitlles M, Martinez-Garcia MA, et al. ROSE: radiology, obstruction, symptoms and exposure - A Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Res. 2021;7(4):00399–2021. doi:10.1183/23120541.00399-2021
   PubMedGoogle Scholar
• Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182:560–598. doi:10.1164/rccm.200912-1843CC
   Web of Science ®Google Scholar
• Henkle E, Curtis JR, Chen L, et al. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J. 2019;54(1):1801896. doi:10.1183/13993003.01896-2018
   PubMed Web of Science ®Google Scholar
• Singanayagam A, Glanville N, Girkin JL, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun. 2018;9(1):2229.
   PubMed Web of Science ®Google Scholar
• Singanayagam A, Glanville N, Cuthbertson L, et al. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Sci Transl Med. 2019;11:507. doi:10.1126/scitranslmed.aav3879
   Web of Science ®Google Scholar
• Contoli M, Pauletti A, Rossi MR, et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4):1700451. doi:10.1183/13993003.00451-2017
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Monteagudo M, Solntseva I, Alcázar B. Blood eosinophil counts and their variability and risk of exacerbations in COPD: a Population-Based Study. Arch Bronconeumol. 2021;57(1):13–20. doi:10.1016/j.arbr.2019.12.021
   PubMed Web of Science ®Google Scholar
• Golpe R, Dacal D, Sanjuán-López P, Martín-Robles I, Pérez-de-llano LA. Plasma eosinophil count and patient-centered events in chronic obstructive pulmonary disease in real-life clinical practice. Arch Bronconeumol. 2020;56(2):129–130. doi:10.1016/j.arbr.2019.09.001
   PubMed Web of Science ®Google Scholar